64 results on '"Creutzberg, Carien L."'
Search Results
2. Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer
3. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
4. Predictive Factors for Toxicity After Primary Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review
5. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
6. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
7. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
8. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy
9. Interpretable Deep Learning Predicts the Molecular Endometrial Cancer Classification from H&E Images: A Combined Analysis of the Portec Randomized Clinical Trials
10. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study
11. Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22)
12. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making
13. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
14. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update
15. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
16. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes
17. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
18. Implementing clinical practice guidelines: time to assess it
19. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
20. Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature
21. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
22. Investigators' response
23. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
24. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome
25. Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?
26. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial
27. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
28. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
29. Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed
30. Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma
31. Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios
32. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial
33. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials
34. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
35. Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials
36. Impact of Cardiovascular Counseling and Screening in Hodgkin Lymphoma Survivors
37. Second primary cancers in survivors of cervical cancer in the Netherlands: Implications for prevention and surveillance
38. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
39. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
40. Long-term risk of secondary skin cancers after radiation therapy for Hodgkin’s lymphoma
41. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation
42. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
43. International Brachytherapy Practice Patterns: A Survey of the Gynecologic Cancer Intergroup (GCIG)
44. Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma
45. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population
46. Rebuttal to Drs. Reed and Harrand
47. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)
48. Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer
49. Long-term outcomes of eye-conserving treatment with Ruthenium106 brachytherapy for choroidal melanoma
50. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.